Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xianlu Bujiu is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Juneng Golden Key Pharmaceutical (Wuhan Juneng Jinshi Pharmaceutical). It is an approved medicinal product in China, categorized as a "Bujiu" or medicinal liquor, though it is sometimes grouped with oral liquids and syrups in manufacturing contexts. The product is indicated for tonic and nourishing use, specifically aimed at replenishing vital energy (Qi), nourishing the kidneys, and strengthening the body's "yang" essence. It is typically used to address symptoms of physical weakness, fatigue, and general deficiency, particularly in elderly populations. As a TCM product, it consists of a complex blend of herbal and animal-derived ingredients, such as deer antler, which work synergistically according to traditional pharmacological principles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xianlu Bujiu.